In the ‘why therapeutic drug monitoring’ debate, we’ve heard a lot about TDM utility, but the con argument is interesting. Desiree van der Heijde compares TDM to IL-6 levels, which never displaced her DAS then puts up some confronting points. Interesting #EULAR2024 @RheumNow https://t.co/7zomungi3e